MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will present its latest advances in gene therapy for blindness diseases at NobleCon21, the annual emerging growth equity conference hosted by Noble Capital Markets, the company announced.
Dr. Shankar Musunuri, Ocugen’s chairman, CEO and co-founder, is scheduled to deliver a presentation and fireside chat at 1 p.m. ET on Dec. 3 in Presentation Room 2 at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida.
Musunuri said he plans to outline Ocugen’s progress toward a goal of submitting three biologics license applications within three years, as well as near-term clinical catalysts expected in 2026. “NobleCon provides a forum to differentiate Ocugen’s scientific platform among our peers in ophthalmology and share how we are addressing major blindness diseases with a single, one-time gene therapy for life,” he said.
Ocugen executives will also hold one-on-one meetings with investors during the conference to discuss the company’s modifier gene therapy platform and development strategy. A high-definition webcast of the presentation will be made available the following day on the company’s website, Noble’s conference platform and Channelchek, with access archived for 90 days.
Ocugen is developing a gene-agnostic approach to treating complex retinal diseases caused by disruptions across multiple gene networks. Its programs target widespread conditions such as retinitis pigmentosa, Stargardt disease and geographic atrophy—late-stage dry age-related macular degeneration that affects millions worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.